Bristol-Myers Squibb (BMY) Q3 2026 Earnings
Non-GAAP EPS includes a $(0.58) per share net impact from Acquired IPRD charges ($1,558 million) and licensing income; gross margin also reflects a one-time contract termination charge. GAAP EPS of $1.05 additionally reflects $606 million of after-tax specified items, including $458 million amortization of acquired intangibles and $187 million restructuring provision.
How Did BMY Stock React to Q3 2026 Earnings?
Did BMY Beat Earnings? Q3 2026 Results
Yes. Bristol-Myers Squibb reported Q3 2026 earnings of $1.35 a share on Oct 29, 2026, beating the $1.23 consensus estimate by 9.5%. Revenue was $13.1B against a $12.7B estimate.
Bristol Myers Squibb delivered a strong third quarter of 2026, posting adjusted non-GAAP EPS of $1.35 against a consensus estimate of $1.23, a beat of 9.48% that extended the company's winning streak to six consecutive quarters of topping EPS expectations. Revenue climbed 6.9% year over year to $13.07 billion, ahead of the $12.73 billion consensus by 2.67%, powered chiefly by a surging Growth Portfolio that rose 12% to $7.66 billion, with Opdivo Qvantig more than tripling to $334 million and Eliquis jumping 25% to $4.69 billion on robust U.S. demand. Those gains helped offset steep generic-driven declines in Revlimid and Pomalyst, while $1.56 billion in Acquired IPRD charges, net of licensing income, weighed a combined $0.58 on EPS. GAAP gross margin contracted to 68.3% from 71.9%, partly due to a one-time contract termination charge. Looking ahead, management raised full-year revenue guidance to roughly $49.75 billion to $50.25 billion while trimming non-GAAP EPS guidance to $6.35 to $6.55, reflecting the ongoing IPRD and licensing headwind.
- Growth Portfolio revenue rose 12%, led by Opdivo Qvantig, Breyanzi, Reblozyl, Camzyos and Opdualag.
- Eliquis grew 25% worldwide and 39% in the U.S. on demand growth and market share gains.
- Breyanzi gained adoption in the community outpatient setting.
- Camzyos showed strong launch momentum outside the U.S., with international sales up 111%.
- Generic erosion weighed on Revlimid, Pomalyst/Imnovid, Sprycel and Abraxane.
- Gross margin fell on product mix and a one-time contract termination charge.
- SG&A fell 5% and GAAP R&D fell 6%.
- The effective tax rate dropped to 14.1% (non-GAAP) on jurisdictional earnings mix.
- Acquired IPRD charges of $1.6 billion reduced EPS by a net $(0.58).
“We delivered another quarter of double-digit growth in our Growth Portfolio, which increased 12% and reflects the continued momentum across our diversified portfolio.”
Bristol-Myers Squibb CEO, on the earnings call
What Is Bristol-Myers Squibb's Outlook?
BMS raised full-year 2026 non-GAAP revenue guidance to approximately $49.75–$50.25 billion, from $49.0–$50.0 billion, citing broad-based momentum. It lowered non-GAAP diluted EPS guidance to $6.35–$6.55, from $6.75–$7.00, inclusive of a $(0.60) impact from Acquired IPRD and licensing income. Other guidance: - Gross margin of ~69–70%, unchanged. - Operating expenses of ~$16.5 billion, unchanged. - Other income/(expense) of ~$(650) million, improved from ~$(700) million on favorable net interest. - Tax rate of ~18%, unchanged. - Worldwide Eliquis revenue growth of 20–25%. - Legacy Portfolio decline of 3–5%. - Diluted share count of 2,051 million. Upcoming catalysts include Zenbexus Phase 3 PFS data and golcadomide Phase 2 data at ASH, and a mezigdomide PDUFA date of May 13, 2027.
BMY YoY Financials
| Metric | Q3 2026 | Q3 2025 | Year over year |
|---|---|---|---|
| Revenue | $13.1B | $12.2B | +6.9% |
| Net Income | $2.2B | $2.2B | −1.8% |
BMY Revenue by Segment
BMY Revenue by Geography
When Does Bristol-Myers Squibb Report Next?
Figures from SEC filings and company reports. Not investment advice.